Video

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

Author(s):

Kathleen N. Moore M.D.
Conference|SGO Annual Meeting on Women's Cancer

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Illustration of a woman with short gray hair, wearing rectangular-framed glasses.
November 19th 2024

My Top 10 List for Living With Cancer

Kelly Irvin
Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of radiation targeting cancer cells.
November 5th 2024

Common Prostate Cancer Radiation Questions Answered

Alex Biese
Expert answers to patients’ questions were offered as part of the CURE® Educated Patient® Prostate Cancer Summit.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of ovaries.
October 30th 2024

Current Treatment May Be Superior to Recentin In Ovarian Cancer

Spencer Feldman
Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.
Image of doctor consulting man with prostate cancer.
October 22nd 2024

Treatment Side Effects, Quality of Life Factors in Prostate Cancer

Ashley Chan
It’s crucial for patients with prostate cancer to know that all treatments come with side effects, which may affect their quality of life.